Literature DB >> 9570355

Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas.

E M Hartenbach1, T A Olson, J J Goswitz, D Mohanraj, L B Twiggs, L F Carson, S Ramakrishnan.   

Abstract

Vascular endothelial growth factor (VEGF) expression and microvessel density were studied in cases of advanced epithelial ovarian carcinoma to evaluate their usefulness as prognostic variables. Tumor samples from 18 patients with advanced stage serous epithelial ovarian cancer were evaluated for VEGF expression by reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Immunohistochemical study of corresponding archival tissues with an antibody to von Willebrand factor (vWF; FVIII-RA) was used for tumor microvessel count determinations. The correlation of VEGF expression and mean microvessel counts was determined by an unpaired t-test. Survival analysis for known prognostic factors and VEGF expression was performed. Survival distributions were calculated by the product limit of Kaplan and Meier and significant differences between distributions were analyzed with a log rank test. From the RT-PCR analysis of tumor VEGF expression, 12 samples were found to be strongly positive, whereas six samples had low/negative VEGF expression. The median survival was 60 months for the VEGF-low/negative group and 28 months for the VEGF-positive group (P = 0.058). Other prognostic variables had minimal impact on survival, i.e. age < 65 years (P = 0.873), FIGO stage (P = 0.06), grade (P = 0.236) and debulking status (P = 0.842). Fourteen of 18 tumor specimens were suitable for microvessel counting. The mean microvessel counts of the VEGF-positive group and the VEGF-negative group were 27/hpf and 35/hpf, respectively (P = 0.16). In this preliminary analysis, high VEGF expression in epithelial ovarian carcinomas was associated with poor overall survival. Further study will be necessary to elucidate the lack of association of VEGF expression and tumor microvessel counts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9570355     DOI: 10.1016/s0304-3835(97)00350-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  34 in total

1.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

Review 3.  Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies.

Authors:  Pamela J Paley
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

Review 4.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  The clinical significance of vascular endothelial growth factor in malignant ascites.

Authors:  Na Zhan; Wei-Guo Dong; Jing Wang
Journal:  Tumour Biol       Date:  2015-10-13

Review 6.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

7.  Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor.

Authors:  Wei Li; Ru-Jun Xu; Zhen-Yun Lin; Guang-Chao Zhuo; Hong-He Zhang
Journal:  Med Oncol       Date:  2008-11-06       Impact factor: 3.064

8.  Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells.

Authors:  Haitao Luo; Gary O Rankin; Lingzhi Liu; Matthew K Daddysman; Bing-Hua Jiang; Yi Charlie Chen
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

9.  Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.

Authors:  Wei Li; Hong-Ru Jiang; Xiao-Li Xu; Jie Wang; Jun Zhang; Mei-Lin Liu; Ling-Yun Zhai
Journal:  Int J Mol Sci       Date:  2010-10-19       Impact factor: 5.923

10.  A current review of targeted therapeutics for ovarian cancer.

Authors:  Susana M Campos; Sue Ghosh
Journal:  J Oncol       Date:  2010-01-03       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.